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doi:10.1Objective: Patients with severe left ventricular pressure overload secondary to aortic stenosis can present with
signs and symptoms of heart failure despite normal left ventricular ejection fraction. This process occurs, at least
in part, as a result of left ventricular pressure overload–induced extracellular matrix remodeling that promul-
gates increased left ventricular stiffness and impaired diastolic function. However, the determinants that drive
extracellular matrix remodeling in this form of left ventricular pressure overload remain to be fully defined.
Methods: Left ventricular pressure overload was induced in mature pigs (n¼ 15) by progressive ascending aor-
tic cuff inflation (once per week for 4 weeks), whereby left ventricular mass, left ventricular ejection fraction,
and regional myocardial stiffness (rKm) were compared with referent controls (n ¼ 12). Determinants of
extracellular matrix remodeling were assessed by measuring levels of mRNA expression for fibrillar collagens,
matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinase 1 and 4.
Results: With left ventricular pressure overload, left ventricular mass and rKm increased by 2- and 3-fold,
respectively, compared with control, with no change in left ventricular ejection fraction. Left ventricular myo-
cardial collagen increased approximately 2-fold, which was accompanied by reduced solubility (ie, increased
cross-linking) with left ventricular pressure overload, but mRNA expression for fibrillar collagen and matrix
metalloproteinases remained relatively unchanged. In contrast, a robust increase in mRNA expression for tissue
inhibitors of matrix metalloproteinase-1 and 4 occurred with left ventricular pressure overload.
Conclusions: In a progressive model of left ventricular pressure overload, which recapitulates the phenotype of
aortic stenosis, increased extracellular matrix accumulation and subsequently increased myocardial stiffness
were not due to increased fibrillar collagen expression but rather to determinants of post-translational control
that included increased collagen stability (thereby resistant to matrix metalloproteinase degradation) and
increased endogenous matrix metalloproteinase inhibition. Targeting these extracellular matrix post-
translational events with left ventricular pressure overload may hold both diagnostic and therapeutic relevance.
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Shypertrophy occurs and is invariably associated with
increased extracellularmatrix (ECM) remodeling,most nota-
bly fibrillar collagen accumulation.1-4 LVPO with ECM
remodeling can cause increased LV myocardial stiffness,
impaired diastolic function, and signs and symptoms of
heart failure (ie, diastolic dysfunction), despite relatively
preserved LV systolic function, such as normal LV ejection
fractions.1-4 Furthermore, clinical observations suggest the
ECM remodeling that occurs with LVPO secondary to
aortic stenosis is not readily reversible, despite a complete
removal of the overload stimulus.1-4 Moreover, these
persistent changes within the myocardial ECM have been
associated with significant alterations in physiologic and
clinical outcomes, such as LV myocardial stiffness and
survival.5 Thus, identifying the specific mechanisms by
which ECM remodeling occurs in the relevant context of
LVPO holds both scientific and clinical relevance. Although
a large number of studies pertaining to LVPO have been per-
formed in rodents, most notably mice, these model systemsrdiovascular Surgery c Volume 143, Number 1 215
Abbreviations and Acronyms
ECM ¼ extracellular matrix
LV ¼ left ventricular
LVPO ¼ left ventricular pressure overload
MMP ¼ matrix metalloproteinase
TIMP ¼ tissue inhibitor of matrix
metalloproteinase
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Stypically consist of an abrupt and acute induction of the pres-
sure overload stimulus.6,7 As a result, in these murinemodels
of acute LVPO induction, LV systolic function invariably
decreases early and precipitously, which may not
necessarily recapitulate the clinical context of LVPO. Large
animal models of progressive LVPO have been described,
whereby sequential induction of the pressure overload
stimulus was performed, and thereby provides more
relevant changes in LV structure and function to that of the
clinical phenotype of aortic stenosis.8-11 Accordingly, the
overall goal of this project was to develop a large animal
model of LVPO that recapitulates the clinical phenotype of
aortic stenosis and then examine potential transcriptional
and post-transcriptional pathways that may contribute to
the changes in myocardial ECM remodeling in this process.
The myocardial ECM is a complex entity that contains
structural proteins, such as fibrillar collagens, nonstructural
proteins, signalingmolecules, and an array of proteases.12,13
In light of the fact that past studies have identified that the
fibrillar collagens can influence LV myocardial stiffness
properties in the context of LVPO, this was the initial
focus of the present study.1-4 In terms of the fibrillar
collagen matrix, an orchestrated set of events occurs with
respect to expression, synthesis, cross-linking, and degrada-
tion/turnover.14,15 Accordingly, the first objective of the
present study was to measure fibrillar collagen expression,
overall content, and indices of collagen cross-linking in
this large animal model of LVPO. A family of proteases
that play a critical role in ECM degradation are the matrix
metalloproteinases (MMPs), whereby the subclasses of
these MMPs demonstrate different substrate specificities
and biological function.12 Thus, the second objective of
the present studywas to measure the expression of represen-
tative MMPs from each subclass in this model of LVPO. A
control point for overallMMPproteolytic activity is through
endogenousMMP inhibition (tissue inhibitor of matrix met-
alloproteinase [TIMP]).12 Therefore, the third objective of
the present study was to quantify targeted TIMP expression
with LVPO. The central hypothesis of this study was that in
this large animal model of LVPO, increased LV regional
myocardial stiffness would occur in direct association
with fibrillar collagen accumulation and specific post-
transcriptional events in fibrillar collagen processing.216 The Journal of Thoracic and Cardiovascular SurgMATERIALS AND METHODS
The present study developed a model of progressive LVPO in mature
pigs with the overarching aim of inducing significant LV hypertrophy with-
out a compromise on LV ejection fraction, thereby simulating the clinical
phenotype of LVPO. After the development of significant LV hypertrophy,
the present study performed a set of integrated in vivo and ex vivo studies to
define the relationship between changes in regional LV myocardial stiff-
ness and that of myocardial collagen content and stability and MMP/
TIMP profiles. All animals were treated and cared for in accordance with
the National Institutes of Health ‘‘Guide for the Care andUse of Laboratory
Animals’’ (National Research Council, Washington, DC, 1996).
Model of Progressive Left Ventricular Pressure
Overload
Mature Yorkshire pigs (n ¼ 15, 15  1 kg; Hambone Farms, Orange-
burg, SC) were anesthetized with isoflurane (3%/1.5 L/min) and nitrous
oxide (0.5 L/min). Through a left thoracotomy, a 6F vascular access cath-
eter (SlimPort M.R.I. Ultra Low Profile Implanted Port, Bard Access Sys-
tems, Salt Lake City, UT) was inserted and fixed within the descending
thoracic aorta, and its port attachmentwas positionedwithin a subcutaneous
pocket. The pericardium was incised, and a size-matched 12-mm inflatable
Silastic vascular cuff (In Vivo Metric Biomedical Products, Healdsburg,
Calif) was secured around the supracoronary ascending aorta without in-
ducing aortic constriction. A uniform length of Silastic tubing was con-
nected to a second subcutaneous access port for subsequent and serial
engagement (Figure 1). The animals were allowed to recover for 1 week.
Experimental Design
At baseline (day 0) and at weekly intervals thereafter (34), the pigs were
sedatedwith diazepam (200mgorally;Barr Laboratories, Pomona,NY) and
the aortic lines were accessed in sterile fashion for plasma collection
(Figure 1). Transthoracic echocardiographic images (ATL Ultramark VI,
2.25 MHz transducer, Bothell, Wash) of LV mass, volumes, and ejection
fraction were obtained as described previously,16,17 and pressure gradients
were computed from echocardiographic-generated Doppler velocities. On
days 0, 7, 14, and 21, the access ports for the vascular occluders were en-
gaged and injected with fixed and previously determined volumes of
a 10% glycerol solution (in phosphate-buffered saline) to induce controlled
and progressive LVPO.At 5weeks post-LVPO, terminalmeasurementswere
performed to measure indices of LV myocardial stiffness and for tissue col-
lection. Before the terminal end point study, decanted plasma was subjected
to TIMP-1 and 4 analysis using a 2-laser flow cytometric detection system
(Bio-Plex 200, BioRad Laboratories, Hercules, Calif) and a previously val-
idated TIMP platform (TIMP MSA, LKT003; R&D Systems, Minneapolis,
Minn).17 By using precalibrated standards and regression modeling, the
fluorescence emission was converted to an absolute TIMP concentration.
Terminal Studies
After sedation with diazepam (200 mg orally), anesthesia was induced
with sufentanil (2 mg/kg intravenously; Baxter Healthcare Corp, Deerfield,
Ill) and etomidate (0.3 mg/kg intravenously, Bedford Laboratories). After
endotracheal intubation, mechanical ventilation was initiated, and a stable
anesthetic plane was achieved with morphine sulfate (3 mg/kg/h intrave-
nously; Elkins-Sinn, Cherry Hill, NJ) and isoflurane (1%, 3 L/min O2;
Baxter Healthcare Corp). A median sternotomy was performed, the peri-
cardial sac was opened, and a pair of piezoelectric crystals (2 mm; Sono-
metrics, London, Ontario, Canada) was positioned against the LV
anterior free wall endocardial surface to measure segmental wall motion.16
A previously calibrated microtipped transducer catheter was placed in the
LV via a small apical incision (7.5F;Millar Instruments Inc, Houston, Tex).
A vessel loop was placed around the inferior vena cava for transient caval
occlusions. Pressure waveforms and crystal signals were digitized on
a computer for subsequent analysis at a sampling frequency of 1 kHz underery c January 2012
FIGURE 1. A, Experimental design: progressive cuff inflation was used to recapitulate the LV phenotype of LVPO secondary to AS. B, Disengaged 12-mm
inflatable Silastic cuff connected to an implantable subcutaneous port accessed with an angled Huber needle. C, Intraoperative photograph demonstrates
retraction of the main pulmonary artery (*) with fixation of a 12-mm inflatable Silastic cuff around the supracoronary ascending aorta (arrow). LV, Left
ventricular.
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Ssteady-state conditions and during occlusion and release of the caval occlu-
sion, and thereby constructing a family of LV pressure–dimension curves.
The regional myocardial stiffness constant (rKm) was computed using the
logarithmic transformation of the exponential end-diastolic stress–strain
relationship as follows: s ¼ A e(rKm 3) þ B, where s is regional end-
diastolic wall stress, A and B are constants, and 3is the regional strain.17
The hearts were extirpated, and the LV posterior free wall, which was de-
void of any instrumentation, was sectioned and snap-frozen in liquid nitro-
gen for subsequent biochemical analysis of collagen content and MMP and
TIMP expression.18 An additional full-thickness section (2 3 2 cm) was
immersed in 4% formalin solution and processed for histomorphometric
methods. Twelve normal, age-matched, non-instrumented pigs were in-
cluded for comparison purposes.
RNA Isolation and Real-Time Polymerase Chain
Reaction
LV samples (1 g) were homogenized via high-speed shaking (RNeasy
Fibrous Tissue Mini Kit, Qiagen, Valencia, Calif), and total RNAwas ex-
tracted in the presence of DNase. Purified total RNA (1 g) was immediately
reverse transcribed to generate cDNA (iScript cDNA Synthesis Kit;
BioRad Laboratories). All cDNA was stored at80C until analyzed by
quantitative polymerase chain reaction. The cDNA was amplified with
gene-specific primer/probe sets (Universal PCR Master Mix with no Am-
perErase UNG;Cat# 4364321, Applied Biosystems, Foster City, Calif).The Journal of Thoracic and CaThe specific TaqMan primer/probe sets (Applied Biosystems) were
MMP-2 (Cat# Ss03394318_m1), MMP-9 (Cat# Ss03392098_m1),
MMP-7 (Cat# Ss03383345_u1), MMP-13 (Cat# Ss03373279_m1), MT1-
MMP (Cat# Ss03394431_m1), TIMP-1 (Cat# Ss03381944_u1), TIMP-4
(Cat# Hs00162784_m1), collagen 1A1 (Cat# Ss03373340_m1), and
collagen 3A1 (Cat# Ss03375691_g1). In addition, the internal control
primer/probe sets for glucuronidase beta (Gusb, Applied Biosystems, Cat#
Ss03387751_u1 and 18s rRNA, Applied Biosystems, Cat# Hs99999901_s1,
eukaryotic 18S ribosomal rRNA) were analyzed to assess constant expres-
sion levels across samples. Negative controls were run to verify the absence
of genomic DNA contamination (reverse transcription control) and the
absence of overall DNA contamination in the polymerase chain reaction
system and working environment (template control). The real-time poly-
merase chain reaction fluorescence signal was converted to cycle times
and normalized to the mean of the Gusb and 18-s signals.
Collagen Content and Solubility
LV myocardial samples were sequentially extracted as previously de-
scribed.19 Briefly, samples were homogenized in extraction/homogenization
buffer (10mmol/L cacodylic acidpH5.0, 0.15mol/LNaCl, 20mmol/LZnCl,
1.5 mmol/L NaN3, and 0.01%Triton X-100 [v/v]) and centrifuged (800g, 10
minutes, 4C). The supernatant was removed containing soluble collagen,
and the remaining pellet contained insoluble collagen. Protein concentrations
for both fractionswere determined (BicinchoninicAcid protein assay, 23225;rdiovascular Surgery c Volume 143, Number 1 217
TABLE 1. Left ventricular geometry and function with chronic
pressure overload
Control LVPOz
Heart rate (beats/min) 106  5 114  10
Mean arterial pressure (mm Hg) 86  3 92  5
Cardiac output (L/min)y 3.5  0.3 3.3  0.3
Pressure gradient (mm Hg)y 1  1 66  6*
Body weight (kg) 31.6  1.2 28.4  1.2
LV end-diastolic volume (mL)y 50  2 51  3
LV systolic function
LV peak pressure (mm Hg) 100  3 182  8*
Peak positive dP/dt (mm Hg/s) 1601  66 2861  272*
Peak positive dP/dt normalized to
1
16.3  1.0 16.0  1.6
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FIGURE 2. A, LVPO was associated with a marked increase in the LV mass to body weight ratio. B, The LVejection fraction remained unchanged. Thus,
this gradual induction of LVPO caused significant LV hypertrophy without a compromise in LVejection fraction. *P<.05 vs control. LV, Left ventricular;
LVPO, left ventricular pressure overload.
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SThermo Scientific, Rockford, Ill). Collagen concentrations were then
determined using a spectrophotometric assay with picrosirius red.19-21
Briefly, 60 mg of collagen extract and a range of collagen standards (1-64
mg; Collagen Type I, Cat# 08-115, Millipore, Temecula, Calif), were
placed in a 96-well microtiter plate, dried overnight, washed, and incubated
with 0.1% Sirius red F3BA in picric acid (w/v; 1 hour), destained briefly
with 10 mmol/L HCl, and washed. The plate was then subjected to spectro-
photometry (540 nm; VersaMax, Molecular Devices, Sunnyvale, Calif).
The soluble, insoluble, and thus total collagen content per nanogram of total
protein was determined from the standard curve, and the collagen levels were
divided by the original tissueweight toobtain soluble, insoluble, and total col-
lagen per gram of myocardium.
Left Ventricular Myocyte Cross-Sectional Area
For the histomorphometry studies, sections (5 mm) were stained with
hematoxylin–eosin and imaged at a final magnification of 203. Ten
random fields within the mid-myocardial region, devoid of any vascular
compartment, were digitized, and myocyte cross-sectional area was
computed (Sigma Scan, Media Cybernetics Inc, Bethesda,Md). Only those
myocyte profiles whereby the nucleus was centrally located were included
in this analysis.18
Data Analysis
Comparisons between the control and LVPO groups were performed
using the Student t test. Linear regression analysis was performed to
determine correlations between indices of LV diastolic function, such as
regional myocardial stiffness (rKm) to that of collagen biochemistry and
myocyte hypertrophy. Statistical analyses were performed using the
STATA package (Version 8, Intercooled; StataCorp, College Station,
Tex). Data are presented as mean  standard error of the mean.
LV peak pressure (s )
LV diastolic function
LV end-diastolic pressure (mm Hg) 8  1 18  1*
Peak negative dP/dt (mm Hg/s) 2269  206 3186  164*
Peak negative dP/dt normalized to
LV peak pressure (s1)
22.8  1.9 17.7  0.9*
Tau (ms) 29  1 37  1*
Regional myocardial stiffness (rKm) 3.9  0.3 11.2  0.6*
Plasma TIMP profiles
TIMP-1 (pg/mL) 44.7  8.0 135.8  17.5*
TIMP-4 (pg/mL) 74.6  9.5 129.4  14.9*
Sample size (n) 12 15
Values presented as mean  standard error of the mean. LVPO, Left ventricular pres-
sure overload; LV, left ventricular; TIMP, tissue inhibitor of matrix metalloproteinase.
*P<.05 vs control. yComputed from echocardiography or Doppler velocity. zLVPO
produced by sequential constriction of the proximal aorta.RESULTS
Left Ventricular Function and Geometry
In this model of gradual LVPO, the LV mass to body
weight ratio doubled and the LVejection fraction remained
unchanged in the setting of LVPO when compared with ref-
erent age-matched controls (Figure 2). The effects of LVPO
on LV geometry and function are summarized in Table 1.
Although LV mass increased in the LVPO group, body
weight was similar to that of referent controls. LVPO re-
sulted in a peak terminal transaortic gradient of 66  6
mm Hg without hemodynamic compromise as evidenced
by stability with respect to heart rate, mean arterial pressure,218 The Journal of Thoracic and Cardiovascular Surgand cardiac output. In addition, LVend-diastolic volume re-
mained unchanged from referent control values. However,
in marked contrast, indices of LV diastolic function were
significantly impaired in this model of LVPO, as evidenced
by elevated end-diastolic pressure and reduced active relax-
ation rates (tau, negative dP/dt). Moreover, a 3-fold increase
in regional myocardial stiffness (rKm) was observed with
LVPO. Thus, this large animal model of LVPO resulted in
significant LV hypertrophy with no significant compromise
on LV systolic function, but significantly impaired diastolic
function.ery c January 2012
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FIGURE 3. A, Total collagen content was greater with LVPO. B, Total collagen content is determined by soluble and insoluble collagen components. The
soluble:insoluble collagen ratio changed with LVPO and favored an increase in insoluble collagen content indicating increased collagen cross-linking and
collagen stability. C, A relationship between myocardial collagen content and regional myocardial stiffness was evident. D, Collagen 1A1 and collagen 3A1
mRNA expression did not change with LVPO. Thus, the observed increase in collagen content was not due to an increase in fibrillar collagen expression.
LVPO, Left ventricular pressure overload. *P<.05 versus control.
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SLeft Ventricular Myocyte Hypertrophy, Collagen
Content, and Expression
By using histomorphometric methods, LV myocyte
cross-sectional area increased by approximately 2-fold
with LVPO when compared with referent controls (424þ
22 mm2 vs 273þ 5 mm2, respectively, P< .05). Changes
in total myocardial collagen content and solubility with
LVPO are summarized in Figure 3. Total myocardial colla-
gen content increased by approximately 50% with LVPO
and was associated with a greater insoluble collagen frac-
tion- indicative of reduced solubility. However, although to-
tal myocardial collagen increased, there was no significant
change in relative fibrillar collagen type I or type III
mRNA levels (Figure 3). Thus, this model of LVPO resulted
in significant collagen accumulation and decreased solubil-
ity, but no change in the relative expression of the most
common fibrillar collagen types.
Left Ventricular Myocardial Matrix
Metalloproteinase/Tissue Inhibitors of Matrix
Metalloproteinase mRNA Levels and Tissue
Inhibitors of Matrix Metalloproteinase Plasma
Profiles
The relative levels for the different classes of MMP types
and for TIMP-1 and TIMP-4 with respect to referent controlThe Journal of Thoracic and Cavalues are summarized in Figure 4. Relative mRNA levels
for MMPs and TIMPs are summarized in Figure 4. No
change in mRNA levels was observed with LVPO for the in-
terstitial collagenase (MMP-13) or gelatinase MMP sub-
classes. However, in the setting of LVPO, mRNA levels
for matrilysin (MMP-7) decreased and mRNA levels for
the membrane type MMP (MT1-MMP) increased. A robust
increase in mRNA expression for TIMP-1 and 4 was ob-
served with LVPO. The significantly increased myocardial
TIMP-1 and 4 mRNA levels were paralleled by a 3-fold in-
crease in plasma TIMP-1 and more than a 50% increase in
plasma TIMP-4 (Table 1).
Relationship Among Left Ventricular Function,
Hypertrophy, and Collagen
A correlation matrix was developed to determine the
relative association between indices of LV function, par-
ticularly diastolic function, to biochemical and morpho-
metric indices of myocardial remodeling with LVPO. As
would be expected, LV mass was strongly associated
with both myocyte cross-sectional area and total collagen
content (r ¼ 0.80 and 0.67, respectively, both P<.05). LV
isovolumic relaxation and end-diastolic pressure were both
associated with myocyte cross-sectional area (r ¼ 0.60
and 0.75, respectively). For LV myocardial collagenrdiovascular Surgery c Volume 143, Number 1 219
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Scontent, one of the strongest relationships was between
myocardial collagen content and regional myocardial stiff-
ness (Figure 3).
DISCUSSION
Although LVPO is a common clinical problem caused by
both hypertension and aortic stenosis, animal models that
recapitulate the clinical LV phenotype have not been fre-
quently used. LV functional and structural manifestations
of LVPO include impaired LV filling (ie, diastolic dysfunc-
tion) without an early compromise in systolic function and
LV hypertrophy with myocardial fibrillar collagen accumu-
lation. Although a large number of studies have induced
LVPO in murine models6,7 and provided invaluable
molecular clues as to the adaptation of the LV to pressure
overload stimuli, these murine constructs may not
accurately reflect the clinical LV phenotype of LVPO.
Accordingly, the present study used a large animal of
LVPO to identify specific mechanisms and pathways that
may contribute to ECM remodeling with LVPO, and
thereby contribute to the LV myocardial stiffness that
invariably occurs in this pathologic condition. The new
and unique findings from the present study were 2-fold.
First, gradual induction of LVPO in a large animal model
resulted in LV hypertrophy and increased myocardial stiff-
ness, and increased collagen matrix accumulation without
a reduction in LV ejection fraction, thus recapitulating im-
portant features of the clinical phenotype of LVPO. Second,
the collagen accumulation observed in this model of LVPO
was not associated with a robust increase in collagen ex-
pression at the transcriptional level, but rather with major
changes in post-translational processes, such as increased
collagen cross-linking and TIMP induction. These new220 The Journal of Thoracic and Cardiovascular Surgfindings challenge the canonical concept that the increased
collagen accumulation with LVPO is simply due to en-
hanced collagen expression and synthesis, but rather due
to shifts in post-translational processes such as resistance
to degradation and reduced proteolysis.
Left Ventricular Pressure Overload and the
Myocardial Extracellular Matrix
Relief of LVPO, as is typically achieved by surgical cor-
rection of aortic stenosis, facilitates regression of LV hyper-
trophy.1,22 However, structural abnormalities persist within
the myocardial ECM despite appropriate elimination of the
LVPO stimulus and can be associated with suboptimal
clinical outcomes.5,23 For example, Villari and colleagues2
demonstrated that increased ECM accumulation persists
up to several years after aortic valve replacement when
performed for long-standing LVPO. In addition, a recent
investigation conducted by Azevedo and colleagues5 dem-
onstrated that the magnitude of myocardial matrix accumu-
lation at the time of aortic valve surgery was directly related
to postoperative survival. These observations suggest that
in patients with LVPO, an irreversible shift in ECM re-
modeling occurs, after which complete normalization of
LV matrix structure may be precluded. The present study
began to address this clinically relevant issue through
identifying contributory mechanisms that likely underlie
ECM remodeling with LVPO. The outcomes from this ini-
tial investigation suggest that specific post-translational
pathways are altered in this pathologic process. Moreover,
this LVPO model may be useful in guiding the identifica-
tion of specific and potentially irreversible steps in the
ECM remodeling in the context of LVPO. However, it
must be recognized that a major determinant of the myo-
cardial remodeling process with LVPO is predominantly
characterized by myocyte hypertrophy, which was demon-
strated in the present study. Indeed, the present study dem-
onstrated strong associations between the indices of active
relaxation and the degree of myocyte hypertrophy. Thus, it
is likely the summation of both cellular and extracellular
processes that give rise to significantly impaired LV filling
and ultimately the presentation of heart failure. Another
important consideration of the present study is that only
indices of fibrillar collagen content and expression were
considered, and these structural components actually com-
prise a small volume fraction of the entire ECM. The pres-
ent study did not consider other constituents of the
myocardial ECM, which include membrane bound and
soluble bioactive molecules, as well as other proteins
that contribute to the structure and biophysical properties
of the ECM, such as the proteoglycans and glycosamino-
glycans. Nevertheless, the present study does provide
a foundation for future studies in a relevant large animal
model of LVPO by which to examine other constituents
of the ECM and critical signaling molecules that likelyery c January 2012
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pathologic stimulus.
Left Ventricular Pressure Overload and
Extracellular Matrix Post-Translational Events
This study assessed the effects of LVPO on myocardial
collagen content and collagen stability. LVPO was associ-
ated with a significant increase in myocardial collagen con-
tent. Moreover, insoluble collagen content, indicative of
collagen cross-linking and stability, was also increased
with LVPO, and a relationship between myocardial colla-
gen content and regional myocardial stiffness was demon-
strated. Of note, these changes in collagen content and
cross-linking occurred in the absence of demonstrable
changes in mRNA
fibrillar collagen levels. Although these measurements were
performed at one point in time, and only after the LV re-
modeling process with LVPO had become manifest, these
findings do suggest that persistent collagen transcriptional
activity is not the sole determinant of matrix accumulation.
Important post-transcriptional/translational determinants of
ECM remodeling include the MMPs and TIMPs. MMPs are
a large family of proteolytic enzymes that include both
soluble and membrane bound species.12 These enzymes
are capable of degrading all components of the ECM, and
their activity is regulated by TIMPs.12 MMP activity and
TIMP abundance have been linked to myocardial fibrosis
in LVPO.9,11,24-26 This study examined the change in
mRNA levels for selected MMPs from various classes,
including the gelatinases, matrilysins, collagenases, and
membrane-type MMPs. Despite significant LV hypertrophy
and ECM accumulation, no parallel change in the ubiqui-
tous collagenase MMP-13 or the gelatinases MMP-2 or 9
occurred. Other MMP types (eg, MMP-7) were actually re-
duced with LVPO. MMP-7 is an MMP type expressed in
macrophages and fibroblasts.27 Although it remains specu-
lative, the relative reduction in this MMP type suggests that
a phenotypic change in these cell types occurred with
LVPO. However, the current study did not quantify or iso-
late these critical cell types that likely contributed to
changes in the structure and function of the ECM with
LVPO. In contradistinction to the above observations, the
membrane-type MMP, MT1-MMP, increased with LVPO.
This MMP-type processes a number of biological signaling
molecules, most notably the profibrotic moiety transform-
ing growth factor.28 For example, in a recent study, myocar-
dial overexpression of MT1-MMP did not result in ECM
degradation, but rather enhanced myocardial fibrosis.28
Thus, the induction of this MT1-MMP type would be con-
sistent with the fibrillar collagen accumulation observed in
the present study with LVPO.
A crucial determinant of the myocardial ECM structure is
the interaction between theMMPs and their endogenous tis-
sue inhibitors, or TIMPs.28 TIMPs are small molecularThe Journal of Thoracic and Caweight proteins that can demonstrate a diversity of biologic
functions29,30 beyond that of MMP inhibition alone. For
example, TIMPs can facilitate ECM accumulation not
only by attenuating overall net MMP proteolytic activity
but also by inducing profibrotic cascades in and of
themselves.31 In the present study, LVPO caused a robust
increase in TIMP-1 and TIMP-4 mRNA levels that paral-
leled fibrillar matrix accumulation. These particular TIMPs
have been identified to regulate fibroblast growth, viability,
and proliferation in vitro.31 Thus, the induction of these
TIMPs with LVPO likely altered several cellular and bio-
logical processes relevant to fibrillar collagen accumulation
from reducing MMP activity, inducing profibrotic path-
ways, and enhancing fibroblast function. Although remain-
ing speculative, it is likely that the induction of these TIMPs
may constitute an important event in the progression of
ECM remodeling and LV diastolic dysfunction that occurs
with LVPO. Indeed, clinical studies of LVPO have identi-
fied that increased plasma levels of TIMP-1 and 4 occur
in patients with developing heart failure, secondary to dia-
stolic dysfunction.17,24 In the present study, the diastolic
dysfunction that occurred secondary to the induction of
LVPO resulted in a significant increase in plasma levels
of TIMP-1 and 4. The relative magnitude of the elevated
plasma TIMP profiles observed in this large animal model
of LVPO was similar to that observed previously in patients
with LVPO and diastolic heart failure.18,24 Thus, future
studies focusing on modulating relative TIMP-1 and 4
levels in this model of LVPO may hold both diagnostic
and therapeutic relevance.
CONCLUSIONS
Progressive induction of LVPO in this large animal
model related to LV function and stiffness elicited a unique
matrix signature and was associated with myocardial ECM
remodeling. Specifically, an increase in collagen content
and stability and a reduction in the indices of collagen deg-
radation were observed. These changes seemed to occur in
the absence of increased collagen expression. Finally,
although associative, the present study demonstrated a rela-
tionship between the induction of LVPO, myocyte growth,
and ECM remodeling and the indices of diastolic dysfunc-
tion. Thus, this large animal model of LVPO will allow for
mechanistic assessment of how specific cellular and extra-
cellular pathways may contribute specifically to LV dia-
stolic dysfunction in the absence of severe systolic failure,
an important and clinically relevant scientific objective.32
However, it must also be recognized that no animal model
can completely recapitulate the clinical presentation of
chronic LVPO such as that with aortic stenosis. For exam-
ple, the present study used sequential ascending supravalv-
ular aortic constriction. This model of LVPO would
unlikely cause the changes in coronary blood flow and
therefore the ischemic substrate that would be operativerdiovascular Surgery c Volume 143, Number 1 221
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Sin patients with valvular aortic stenosis. Second, the stepped
and sequential LVPO induced in the present study is
unlikely to completely represent the duration, pattern, and
magnitude that occur in clinical forms of LVPO. Neverthe-
less, this model of LVPO demonstrated significant pheno-
typic similarities to clinical observations of LVPO in
patients in terms of myocardial ECM remodeling and LV
diastolic dysfunction. The model system and paradigms
identified in this article may provide a means to identify
the mechanisms that give rise to pathologic ECM remodel-
ing and the potential point of irreversible ECM remodeling,
and thereby improve the timing and treatment approaches
for elimination of LVPO stimulus.
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Dr Joseph Schmoker (Burlington, Vt). I have no disclosures.
My questions pertain to the miR-1 and 133 that you studied. In
the mouse model, the transverse aortic constriction (TAC) model,
both are actually antihypertrophic and overexpression of miR-133
is associated with down-regulation of collagen in cultured fibro-
blasts. So I’m curious how you interpret this relative to the oppo-
site findings in your large animal model. In addition, did you
perform microarray analysis on myocardium to broaden your
miR phenotype?
DrYarbrough.We have just begun our initial assessments with
respect to miRs. We anticipate performing microarray analysis to
broaden the miR phenotype. I agree these initial preliminary miR
data are at odds with the relatively small amount of data that exist
in the literature with respect to this topic.
At this time, we believe that miR-133 in particular may inhibit
collagen 1A1 and 3A1. Our theory is that with up-regulation of
miR-133, there is inhibition of collagen 1A1 and 3A1 expression.
That would account for the lack of increased collagen expressionery c January 2012
Yarbrough et al Evolving Technology/Basic Sciencenoted in the study. In summary, we believe the increased collagen
content observed in the study was secondary to increased colla-
gen stability and resistance to degradation as opposed to in-
creased collagen expression. With prolongation of the animal
model, we may see a reduction in miR-133 and miR-1 levels
that will then ‘‘release’’ some of the inhibition on the collagen
1A1 and 3A1 genes. That may then lead to a robust increase
in collagen expression, counter to what we’re seeing at this point
in time at 1 month.
Dr Schmoker. My final question is related to how the control
animals were handled at the terminal data collection. My under-
standing from the article is that the controls were not violatedThe Journal of Thoracic and Cafrom the standpoint of manipulation of the heart during final
data collection. Knowing that both miR-1 and 133 can be induced
with myocardial ischemia, could subendocardial ischemia in-
curred from surgical handling and manipulation during terminal
data collection be responsible for the differences in miR expres-
sion in the experimental group relative to controls?
Dr Yarbrough. Perhaps, but I don’t believe that is likely. We
performed microsphere studies on both the control and the instru-
mented animals and showed no difference in perfusion with re-
spect to microsphere data collected from the endocardium,
myocardium, or epicardium. Thus, I don’t think submyocardial is-
chemia was likely.rdiovascular Surgery c Volume 143, Number 1 223
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